. | Women without C-peptide production in early pregnancy . | Women with C-peptide production in early pregnancy . |
---|---|---|
n (%) | 20 (57) | 15 (43) |
Age (years) | 32 (27–40)* | 30 (26–34) |
Duration of diabetes (years) | 20 (6–28) | 16 (2–31) |
Last A1C before pregnancy (%) | 7.5 (6.1–10.0) | 7.6 (6.0–9.3) |
A1C at 8 weeks (%) | 7.1 (5.9–8.7) | 6.8 (5.6–8.8) |
A1C at 33 weeks (%) | 6.0 (5.4–7.2) | 6.0 (5.5–7.1) |
Median change in A1C from 8 to 33 weeks (%) | 0.8 (−0.2 to 2.1) | 0.6 (−0.5 to 2.9) |
Insulin dose before pregnancy (IU/kg) | 0.75 (0.49–1.05) | 0.56 (0.32–1.17) |
Insulin dose at 8 weeks (IU/kg) | 0.74 (0.45–1.04) | 0.77 (0.33–1.14) |
Insulin dose at 33 weeks (IU/kg) | 1.04 (0.72–1.60) | 1.05 (0.52–1.46) |
BMI before pregnancy (kg/m2) | 24.2 (18.4–34.4) | 23.5 (19.7–33.7) |
Weight gain during pregnancy (kg) | 14.3 (5.6–26.8) | 15.0 (8.0–26.0) |
C-peptide concentrations at 8 weeks (pmol/l) | 6 | 22 (7–325) |
C-peptide concentrations at 33 weeks (pmol/l) | 10 (6–16) | 38 (8–472) |
Median change in C-peptide concentrations from 8 to 33 weeks (%) | 67 (0–167)* | 30 (−50 to 3,271) |
Serum glucose concentrations at 8 weeks (mmol/l) | 6.8 (5.5–13.3) | 7.7 (5.1–14.5) |
Serum glucose concentrations at 33 weeks (mmol/l) | 6.7 (5.4–18.3) | 7.6 (5.1–12.8) |
Placental growth hormone concentrations at 8 weeks (ng/ml) | 1.0 (0.1–6.9) | 1.3 (0.2–5.2) |
Placental growth hormone concentrations at 33 weeks (ng/ml) | 36.6 (3.5–157) | 41 (8.2–87) |
IGF-I concentrations at 8 weeks (ng/ml) | 158 (26–234) | 169 (100 to 268) |
IGF-I concentrations at 33 weeks (ng/ml) | 235 (115–483) | 280 (144–331) |
GAD antibody concentrations at 8 weeks (units/ml) | 20.5 (0–250) | 7 (0–250) |
GAD antibody concentrations at 33 weeks (units/ml) | 15 (0–250) | 6 (0–129) |
. | Women without C-peptide production in early pregnancy . | Women with C-peptide production in early pregnancy . |
---|---|---|
n (%) | 20 (57) | 15 (43) |
Age (years) | 32 (27–40)* | 30 (26–34) |
Duration of diabetes (years) | 20 (6–28) | 16 (2–31) |
Last A1C before pregnancy (%) | 7.5 (6.1–10.0) | 7.6 (6.0–9.3) |
A1C at 8 weeks (%) | 7.1 (5.9–8.7) | 6.8 (5.6–8.8) |
A1C at 33 weeks (%) | 6.0 (5.4–7.2) | 6.0 (5.5–7.1) |
Median change in A1C from 8 to 33 weeks (%) | 0.8 (−0.2 to 2.1) | 0.6 (−0.5 to 2.9) |
Insulin dose before pregnancy (IU/kg) | 0.75 (0.49–1.05) | 0.56 (0.32–1.17) |
Insulin dose at 8 weeks (IU/kg) | 0.74 (0.45–1.04) | 0.77 (0.33–1.14) |
Insulin dose at 33 weeks (IU/kg) | 1.04 (0.72–1.60) | 1.05 (0.52–1.46) |
BMI before pregnancy (kg/m2) | 24.2 (18.4–34.4) | 23.5 (19.7–33.7) |
Weight gain during pregnancy (kg) | 14.3 (5.6–26.8) | 15.0 (8.0–26.0) |
C-peptide concentrations at 8 weeks (pmol/l) | 6 | 22 (7–325) |
C-peptide concentrations at 33 weeks (pmol/l) | 10 (6–16) | 38 (8–472) |
Median change in C-peptide concentrations from 8 to 33 weeks (%) | 67 (0–167)* | 30 (−50 to 3,271) |
Serum glucose concentrations at 8 weeks (mmol/l) | 6.8 (5.5–13.3) | 7.7 (5.1–14.5) |
Serum glucose concentrations at 33 weeks (mmol/l) | 6.7 (5.4–18.3) | 7.6 (5.1–12.8) |
Placental growth hormone concentrations at 8 weeks (ng/ml) | 1.0 (0.1–6.9) | 1.3 (0.2–5.2) |
Placental growth hormone concentrations at 33 weeks (ng/ml) | 36.6 (3.5–157) | 41 (8.2–87) |
IGF-I concentrations at 8 weeks (ng/ml) | 158 (26–234) | 169 (100 to 268) |
IGF-I concentrations at 33 weeks (ng/ml) | 235 (115–483) | 280 (144–331) |
GAD antibody concentrations at 8 weeks (units/ml) | 20.5 (0–250) | 7 (0–250) |
GAD antibody concentrations at 33 weeks (units/ml) | 15 (0–250) | 6 (0–129) |
Data are median (range) unless indicated otherwise.
*P < 0.05.